• Home >
  • Publications >
  • CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study

CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study

1 Aug 2015The Lancet Oncology

DOI : 10.1016/s1470-2045(15)00132-1

Authors

Philippe A Cassier, Antoine Italiano, Carlos A Gomez-Roca, Christophe Le Tourneau, Maud Toulmonde, Michael A Cannarile, Carola Ries, Anne Brillouet, Claudia Müller, Anna-Maria Jegg, Ann-Marie Bröske, Markus Dembowski, Katharine Bray-French, Christine Freilinger, Georgina Meneses-Lorente, Monika Baehner, Ross Harding, Jayantha Ratnayake, Keelara Abiraj, Nathalie Gass, Karen Noh, Randolph D Christen, Lidia Ukarma, Emmanuelle Bompas, Jean-Pierre Delord, Jean-Yves Blay, Dominik Rüttinger